# Lucius Cary

> Lucius Cary is a seed investor at Oxford Technology Management backing Medical and Biopharma. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Oxford Technology Management](https://shizune.co/investors/profile/oxford-technology-management)
- Location: Oxford, United Kingdom
- Total investments: 2
- Last investment: Aug 2017
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/lucius-cary-a497375/
- Facebook: https://www.facebook.com/lucius.cary.3

Lucius Cary is a seed investor at Oxford Technology Management in Oxford focused on Medical and Biopharma. Lucius Cary is the founder and managing director of Oxford Technology. He has a degree in engineering and economics from Oxford University, an MBA from Harvard Business School and was an engineering apprentice at the Atomic Energy Research Establishment, Harwell.After forming and raising finance for his first business in 1972, he founded"Venture Capital Report" in 1978 and was its managing director for 17 years. In March 1996, he became chairman and reduced his day-to-day involvement in order to concentrate more fully on Oxford Technology Management's investment activities. Oxford Technology Management raised its first fund to invest in start-up and early-stage technology companies in 1983. In 2003, he was awarded an OBE for services to business.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 50% |
| Biopharma | 1 | 50% |
| Health Care | 1 | 50% |
| Biotechnology | 1 | 50% |
| Pharmaceutical | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 50% |
| Angel | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Ducentis BioTherapeutics | Ducentis is a pre-clinical stage company aiming to develop novel therapies for inflammation and autoimmune disease. Our target is the CD200/CD200R axis which imparts a deactivating signal to activated immune cells in both the innate and adaptive arms of the immune system. Potential therapeutic targets include transplant rejection andautoimmune and inflammatory disease affecting the lung, liver, kidney, eye, bone and cartilage. | $1M | Angel | Aug 01, 2017 |  |
| Ducentis BioTherapeutics | Ducentis is a pre-clinical stage company aiming to develop novel therapies for inflammation and autoimmune disease. Our target is the CD200/CD200R axis which imparts a deactivating signal to activated immune cells in both the innate and adaptive arms of the immune system. Potential therapeutic targets include transplant rejection andautoimmune and inflammatory disease affecting the lung, liver, kidney, eye, bone and cartilage. | $105K | Seed | Dec 14, 2015 |  |

2 of 2 investments shown.

## Co-investors
- [Capital Cell](https://shizune.co/investors/profile/capital-cell) — VC Fund, 1 deal together

## About Oxford Technology Management

VC Fund · Oxford, United Kingdom

Oxford Technology Management was founded by Lucius Cary, and since 1983 has specialised in making and managing investments in start-up and early stage technology-based businesses with high growth prospects.The OTM team are all scientists or engineers by background, and understanding the technology is the starting point for any investment thatthey may make.The Investment policy of Oxford Technology Management is to construct a portfolio of investments with the following characteristics:unlisted, UK based, technology businesses investments typically in the range of £100,000 - £2,000,000, although it can then invest similar amounts in subsequent rounds in most cases located within easy reach of Oxford to allow a more 'hands on' management strategy It is expected that approximately half of the funds will be invested in early stage companies (those which have achieved some initial sales) and the balance in start-up companies which are at an earlier stage.

4 contacts available at Oxford Technology Management.

| Name | Title | Profile |
| --- | --- | --- |
| Andrea Mica | Director | https://shizune.co/investors/profile/andrea-mica |
| David Livesley | Non-Executive Chairman | https://shizune.co/investors/profile/david-livesley |
| Lucius Cary | Founder and Managing Director | https://shizune.co/investors/profile/lucius-cary |
| Michael Penington | Partner | https://shizune.co/investors/profile/michael-penington |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Lucius Cary invest in?

Lucius Cary invests primarily in Medical, Biopharma and Health Care startups, most often at Seed and Angel stage. Most of the 2 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Lucius Cary last invest?

The most recent investment recorded for Lucius Cary closed in Aug 2017. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co